文献速递眼底病与葡萄膜炎

阿柏西普治疗新生血管性年龄相关性黄斑变性12个月结局:固定方案与按需方案比较

TWELVE-MONTH OUTCOMES OF INTRAVITREAL AFLIBERCEPT FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: Fixed Versus As-needed Dosing.
PubMed 文献 · Retina · 2019-01-01

这项前瞻性多中心、非劣效性、倾向评分匹配研究比较了阿柏西普固定方案与PRN方案治疗新生血管性AMD的12个月结局。匹配后每组92眼,两组视力均改善,但PRN方案在第8个月和第12个月均未能显示非劣效于固定方案。固定组全部接受7次注射,PRN组平均5.5±1.6次。

要点

  • 固定方案组全部接受7次注射,PRN组平均5.5±1.6次注射。
  • 第4个月时固定与PRN方案等效,平均差异1.75个ETDRS字母。
  • PRN方案在第8和第12个月均未显示非劣效于固定方案。

核心结论

  • 阿柏西普固定治疗方案比个体化PRN方案产生更好的视力结局。

研究设计与样本

  • 前瞻性多中心、非劣效性、倾向评分匹配研究,评估阿柏西普按标签固定方案或PRN方案治疗的12个月结局。
  • PRN组接受一次初始注射,随后每月随访并按需再治疗。
  • 一对一匹配后固定组和PRN组各包含92只眼。

主要发现

  • 两组视力从基线至12个月均改善。
  • 第4个月时固定方案与PRN方案等效,平均差异1.75个ETDRS字母(95%CI:-1.42至+4.92)。
  • PRN方案在第8个月未能显示非劣效于固定方案,平均差异3.43个ETDRS字母(95%CI:+0.25至+6.22)。
  • PRN方案在第12个月未能显示非劣效于固定方案,平均差异4.83个ETDRS字母(95%CI:+1.37至+8.29)。
  • 固定组全部患者接受7次注射,PRN组平均接受5.5±1.6次治疗。

临床怎么用

  • 对于新生血管性AMD患者,阿柏西普固定治疗方案可能比PRN方案提供更好的视力结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To compare the clinical outcomes of aflibercept used with a fixed schedule with a pro-re-nata (PRN) retreatment regimen in patients affected by neovascular age-related macular degeneration. METHODS: This is a prospective multicenter, noninferiority, propensity score-matched study evaluating the 12-month outcomes of aflibercept given either according to labeling or following a PRN regimen. Patients included in the latter group received one initial injection, followed by monthly visits and as-needed retreatment. RESULTS: One-to-one matching resulted in fixed and PRN arms containing 92 eyes each. Visual acuity improved from baseline to 12 months in both the study groups. At Month 4, the fixed regimen was equivalent to the PRN regimen (mean difference: 1.75 Early Treatment Diabetic Retinopathy Study letters, 95% confidence interval: -1.42 to +4.92). The pro-re-nata regimen failed to show noninferiority compared with the fixed regimen at both Month 8 (mean difference: 3.43 Early Treatment Diabetic Retinopathy Study letters, 95% confidence interval: +0.25 to +6.22) and Month 12 (mean difference: 4.83 Early Treatment Diabetic Retinopathy Study letters, 95% confidence interval: +1.37 to +8.29). All patients in the fixed group received seven injections. Patients included in the PRN arm received a mean of 5.5 ± 1.6 treatments. CONCLUSIONS: Aflibercept given with a fixed treatment regimen produces better visual acuity outcomes than an individualized regimen.

来源:Retina,查看原文。版权归原作者所有。

引用

  1. Veritti D, Sarao V, Missiroli F, et al. TWELVE-MONTH OUTCOMES OF INTRAVITREAL AFLIBERCEPT FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: Fixed Versus As-needed Dosing. Retina. 2019. PMID: 30161093. doi:10.1097/IAE.0000000000002299

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。